Telix Pharmaceuticals Limited (TLX) Stock Analysis & Winston Score

Telix Pharmaceuticals is an Australian biotechnology company that makes radioactive medicines used to find and treat cancer. Its main product, Illuccix, is a diagnostic imaging agent that helps doctors detect prostate cancer by making tumors visible on PET scans. The company sells primarily to hospitals, imaging centers, and nuclear medicine specialists, mostly in the United States. Telix earns revenue by selling these radiopharmaceutical products directly to healthcare providers, with Illuccix driving the large majority of its sales. The company is headquartered in Melbourne, Australia, but generates most of its revenue in the US market, where it has built a commercial manufacturing and distribution network. With a market cap around $3.6 billion and a gross margin above 50%, the business is profitable at the product level but still investing heavily in expanding its pipeline of cancer-targeting treatments — meaning its ability to successfully develop and commercialize additional radiopharmaceutical candidates will be the key driver of long-term growth.